I initially thought he was partially justified in claiming the number with the 'mild-to-medium patients' qualification if there was a real benefit in the drug t

I initially thought he was partially justified in claiming the number with the 'mild-to-medium patients' qualification if there was a real benefit in the drug that the study had not been designed to detect. Except that a follow up study focusing on the mild-to-medium subgroup failed to show statistically significant benefits.